Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer

  • Technology appraisal guidance
  • TA1030
  • Published: 

History

Documents created during the development process.

Declaration of interests

Final draft guidance

Draft guidance

Invitation to participate

Notes